Navigation Links
Roche Acquires RALS IT Connectivity Assets to Strengthen Presence in Point-of-Care Information Management

INDIANAPOLIS, Oct. 13 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Medical Automation Systems, Inc. (MAS) announced today that they have signed an agreement under which Roche will acquire certain assets from MAS, a Charlottesville, Virginia-based privately held company. Under the terms of the agreement, Roche will acquire all the assets associated with the RALS point-of-care (POC) information technology (IT) connectivity system, as well as the names "Medical Automation Systems," "MAS" and "RALS." As part of the transaction, Roche expects to retain substantially all of the MAS employees.

"As a global leader in POC testing, Roche is committed to helping improve the quality of patient care by providing products that support clinical decision-making," said Jack Phillips, president and CEO of Roche Diagnostics Corporation North America. "Information management plays an increasingly critical role to meet the growing needs of our POC customers. With this acquisition, we will build on our strategy to deliver integrated testing solutions to our customers."

MAS is the market leader in POC information management with the RALS POC IT connectivity system, used in over 2,000 hospitals in the United States (USA). MAS pioneered the use of IT systems to improve the efficiency and regulatory compliance of hospital POC programs. Over the past decade, MAS has consistently brought innovative functionality to the market through collaborative development with its diagnostic partners.  

"MAS and Roche have had a close partnership for over ten years to co-market RALS for hospital blood glucose testing in the US" said Kurt Wassenaar, chief executive officer of MAS. "Roche is the ideal company to build upon the RALS system and deliver the next generation of information management systems. We're very pleased that Roche has decided to acquire these assets and is committed to ensuring the continued success and support of the RALS products and pipeline."

Roche Diagnostics develops and commercializes innovative solutions in the field of serum-based laboratory and POC testing, including CoaguChek® and ACCU-CHEK® brand products used by healthcare professionals to monitor coagulation and blood glucose at the point of care. They are currently used with the RALS information management systems in healthcare facilities across the US.

"The acquisition of RALS assets is a perfect fit with our strategy to deliver market-leading IT connectivity solutions. It further complements our IT product portfolio," stated Peter Finckh, Head of Global Platforms and Support Roche Diagnostics. "With this acquisition, we gain a very talented group of people with strong expertise and domain knowledge in POC IT, which we expect to be instrumental in delivering future generations of POC -IT solutions in collaboration with existing forces. It will further enable our mission to provide leading integrated testing solutions for our customers."

As part of Roche, RALS will remain a vendor-neutral IT connectivity solution and Roche will continue to expand the number of device interfaces available, enabling customers to streamline POC management in their hospitals.  

This transaction is subject to customary closing conditions. Upon closing, the legal entity currently known as MAS will be renamed.

About MASMAS, a leading provider of POC information management systems, is based in Charlottesville, Virginia, USA.  In addition to the RALS system, MAS provides informatics solutions for critical care applications including inpatient IV insulin dosing software and ICU outcomes reporting software, as well as analytical services.  

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: or

All trademarks used or mentioned in this release are protected by law.For further information, please contact: Betsy CoxDirector, Corporate CommunicationsRoche Diagnostics CorporationIndianapolis, IN(317)

SOURCE Roche Diagnostics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/29/2015)... Viejo, CA (PRWEB) , ... November 29, 2015 ... ... an all new and unique analog distortion effect tool designed specially for Final ... their footage, and create limiltess looks with the easy-to-use modification controls. Destoying and ...
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
Breaking Medicine News(10 mins):